Tiziana Life Sciences plc ( Tiziana or the Company ) Agreement with STC Biologics Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody f

Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody

for Clinical Studies in Patients with COVID-19.

York/London - 29 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"),

a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announces

the execution of an agreement with STC Biologics, Inc. ("STC") for GMP manufacturing of TZLS-501, an anti-IL-6 receptor

(anti-IL-6R) monoclonal antibody (mAb) acquired from Novimmune in 2017, currently in agreement with Bristol Myers Squibb (BMS).

is simultaneously developing an inhalation technology, in collaboration with Sciarra Laboratories, for the direct delivery of

TZLS-501 into the lungs using a handheld inhaler or nebulizer for treatment of patients with COVID-19. The proprietary novel technology

to administer TZLS-501 directly into the nasal passages or lungs by inhaler or nebulizer has potentially significant clinical

advantages for the treatment of COVID-19 patients.

Company recently submitted a patent application for the inhalation delivery of anti-IL6R-monoclonal antibody for the treatment

a unique and best-in-class anti-IL-6R mAb, follows a dual mechanism by not only blocking downstream signaling pathways from membrane-bound

and soluble IL-6 receptors, but it also rapidly depletes blood-stream levels of IL-6, the major culprit for cytokine release syndrome

(CRS) in lungs of COVID-19 patients. In receptor binding assays, TZLS-501 is considerably more potent than the other anti-IL-6R

mAb in this class, such as Actemra (Roche)1,2. These biochemical features, differentiating

TZLS-501 from other mAbs in this class, offer potential distinctive clinical advantages in effecting a rapid suppression of the

cytokine storm at much lower doses.

proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir (Roche) to

lungs could potentially be a transformational therapy for developing a rapid treatment of COVID-19

are aggressively advancing GMP manufacturing of TZLS-501 concurrently with the development of inhalation technology using a hand-held

nebulizer and safety toxicology studies in cynomolgus monkeys. Our objective is to submit an Investigational

New Drug (IND) Application in the first quarter of 2021 for the treatment of COVID-19 patients," said Kunwar Shailubhai,

Ph.D., CEO and CSO of Tiziana Life Sciences.

initiation of GMP manufacturing of TZLS-501 with STC is a timely step forward toward expediting development of a potentially innovative

treatment for COVID-19 patients. We are very excited and well positioned to accelerate the development of TZLS-501 for COVID-19

patients in such extraordinary times," added Dr. Magdalena Leszczyniecka, President and CEO of STC Biologics. "Our

state-of-the-art single use production facility, highly cross-trained experienced personnel, and nimble decision-making has provided

unprecedented speed to clinic in prior GMP campaigns. Together with a strong track record of pharmaceutical, regulatory and process

development know-how, we are uniquely positioned to advance TZLS-501 to the clinic."

Laboratories, Inc., has been developing and manufacturing pharmaceutical aerosol products for over 25 years. Previously, Sciarra

worked with Tiziana to successfully manufacture clinical supplies for the nasal administration of Foralumab, a fully human anti-CD3

mAb, for the recently completed Phase 1 trial3, and the company is currently working with Tiziana to manufacture

Foralumab for nasal administration using a medical device, which will also be used for the upcoming Phase 2 trial in progressive

multiple sclerosis. This phase 2 trial will commence shortly at the Brigham and Women's Hospital, Harvard Medical School,

TZLS-501 (anti-IL-6R mAb)

a fully human mAb, was acquired from Novimmune, a Swiss biotechnology company, in 2017. The cytokine, IL-6, a major determinant

in the priming of pathogenic T cells to produce an inflammatory response, binds to its receptor subunit IL-6R on the cell

membrane. The receptor IL-6R (IL-6R alpha) can be shed as a soluble entity, sIL6R , which binds to circulating IL-6

cytokine in the blood. The downstream signaling from this complex mediates the pro-inflammatory effects underlying the inflammatory

diseases such as rheumatoid arthritis (RA) and acute respiratory distress syndrome (ARDS). The Company believes that the novel

features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling by the membrane-bound and soluble IL-6 receptor

and the rapid depletion of circulating IL-6 cytokines, a major cause of lung damage, suggests a potential role for TZLS-501 in

patient management and treatment of COVD-19. The Company licensed TZLS-501 from Novimmune, a Swiss biotechnology company, in 2017.

Tiziana Life Sciences

Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human

disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab

is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential

application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis ("NASH"),

ulcerative colitis, multiple sclerosis, type-1 diabetes ("T1D"), Crohn's disease, psoriasis and rheumatoid arthritis,

where modulation of a T-cell response is desirable.

Inc. is a boutique biologics CDMO located in Newton, MA that provides full CMC services to enable its partners advance

their biologic products from discovery to commercial approval. Founded in 2009, STC has established its reputation as a flexible

organization that clients can turn to for accelerated low cost programs or custom development when template processes don't

work. STC's new 4000 sq ft state-of-the-art, single-use manufacturing suites and a second smaller clean room suite provides

flexibility and cost saving for clients with vastly different product demands. STC's team brings 100+ years of collective

expertise in biologics drug development from global biopharmaceutical companies. The cross-training of its scientists

in diverse fields with integration of biology and regulatory sciences into process development is what makes STC unique in

its ability to efficiently develop complex biological products. STC Biologics strives to realize "Speed to Clinic"

through integrated product development, technical rigor, and flexibility.

Sciarra Laboratories

Laboratories, Inc., has been a leader in the development of aerosol pharmaceutical products

since 1957 and has been developing and manufacturing pharmaceutical aerosol products at its FDA-approved, cGMP manufacturing

facility located in Hicksville, New York since 1991. Its product line ranges from topical foams, gels, and sprays to metered dose

inhalers (MDI) and nasal sprays. Sciarra manufactures OTC, NDA and medical device products. Sciarra has developed over 50 formulations.

Sciarra offers a turnkey operation from development, validation, and manufacturing services.

statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts

but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs;

and assumptions. Words such as anticipates,' expects,' intends,' plans,' believes,'

'seeks,' estimates,' and similar expressions are intended to identify forward-looking statements. These

statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors,

some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially

from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security

holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the

date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which

the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking

statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required

by law or by any appropriate regulatory authority.